An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes

Leukemia Research Reports

Volumn 3, Issue 2, 2014, Pages 58-61

  Goldberg, Stuart L ^a   Fenaux, Pierre ^b   Craig, Michael D ^c   Gyan, Emmanuel ^d   Lister, John ^e   Kassis, Jeannine ^f   Pigneux, Arnaud ^g   Schiller, Gary J ^h   Jung, JungAh ⁱ   Jane Leonard, E ⁱ   Fingert, Howard ⁱ   Westervelt, Peter ^j  

^a HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CNRS   (France)

^e WESTERN PENNSYLVANIA HOSPITAL   (United States)

^f MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^g BORDEAUX UNIVERSITY HOSPITAL   (France)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^j WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Acute myeloid leukemia (AML); Alisertib; Aurora A kinase inhibitor; Myelodysplastic syndrome (MDS); Safety

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALISERTIB; AZACITIDINE; CYTARABINE; IDARUBICIN;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; CANCER RADIOTHERAPY; CAUSE OF DEATH; COUGHING; DIARRHEA; DISEASE COURSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EXPLORATORY RESEARCH; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROINTESTINAL INFECTION; HEMATOLOGIC DISEASE; HUMAN; HUMAN CELL; KIDNEY FAILURE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; OPEN STUDY; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RESPIRATORY FAILURE; SEPSIS; SIDE EFFECT; SOMNOLENCE; STOMATITIS; SUBDURAL HEMATOMA; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

EID: 84907486048     PISSN: 22130489     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lrr.2014.06.003     Document Type: Article

References (10)

1. Manfredi M.G., Ecsedy J.A., Meetze K.A., Balani S.K., Burenkova O., Chen W., et al. Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc Natl Acad Sci USA 2007, 104:4106-4111.
2. Kelly KR, Ecsedy J, Medina E, Mahalingham D, Padmanabhan S, Nawrocki ST, et al. The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib. J Cell Mol Med 2011, 15:2057-2070.
3. Kelly KR, Nawrocki ST, Espitia CM, Zhang M, Yang JJ, Padmanabhan S, et al. Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism. Int J Cancer 2012, 131:2693-2703.
4. Cervantes A, Elez E, Roda D, Ecsedy JA, Macarulla T, Venkatakrishnan K, et al. Phase I pharmacokinetic/pharmacodynamic study of MLN8237 - an investigational, oral, selective, Aurora A Kinase inhibitor - in patients with advanced solid tumors. Clin Cancer Res 2012, 18:4764-4774.
5. Dees EC, Cohen RB, von Mehren M, Stinchcombe TE, Liu H, Venkatakrishnan K, et al. Phase I study of Aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations. Clin Cancer Res 2012, 18:4775-4784.
6. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003, 21:4642-4649.
7. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006, 108:419-425.
8. Hirota T, Kunitoku N, Sasayama T, Marumoto T, Zhang D, Nitta M, et al. Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. Cell 2003, 114:585-598.
9. Boss DS, Beijnen JH, Schellens JH. Clinical experience with aurora kinase inhibitors: a review. Oncologist 2009, 14:780-793.
10. Dar AA, Goff LW, Majid S, Berlin J, El-Rifai W. Aurora kinase inhibitors - rising stars in cancer therapeutics. Mol Cancer Ther 2010, 9:268-278.